Breaking News

Regeneron, SillaJen in Clinical and Supply Pact

To evaluate Regeneron's PD-1 inhibitor in combination with SillaJen's Pexa-Vec in kidney cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron Pharmaceuticals and SillaJen, Inc. have entered a new clinical and supply agreement for a Phase Ib dose-escalation study in kidney cancer. The study will evaluate Regeneron’s PD-1 inhibitor, REGN2810, in combination with SillaJen’s oncolytic vaccinia virus, Pexa-Vec, in patients with previously treated metastatic or unresectable renal cell carcinoma.             The trial is designed to evaulate the safety and efficacy of REGN2810 in combination with Pexa-Vec compared to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters